Kanazawa K, Honma S, Yuzawa H, Takeuchi S
Gan To Kagaku Ryoho. 1984 Jun;11(6):1276-83.
Human fibroblast interferon (IFN-beta) was given 13 cases of advanced gynecological cancers. Eight patients, who were clinically evaluable, were reported as follows; Patients consisted of ovarian adenocarcinoma (5), cervical adenocarcinoma (1), endometrial carcinoma (1) and tubal carcinoma (1). Route of administration was intravenous in 5 cases and intratumorous in 3 cases. IFN-beta dose ranged from 2, 650 X 10(4) to 10, 620 X 10(4) units. Clinical effects according to Koyama - Saitoh 's category was progressive disease (PD) in 7 cases and minor response (MR) only in one case who received intratumorous injection for recurrent tumor mass of tubal carcinoma in vaginal stump. Side effects of IFN-beta were chill and fever, fatigue and anorexia, leucocyte--and thrombocyte-- penia and hepatic dysfunction, though they were mild in grade and not dose-limiting factors. No anti-IFN-beta-antibodies were detected in any cases.
对13例晚期妇科癌症患者给予人成纤维细胞干扰素（IFN-β）。报告了8例临床可评估的患者，具体情况如下：患者包括卵巢腺癌（5例）、宫颈腺癌（1例）、子宫内膜癌（1例）和输卵管癌（1例）。给药途径为静脉注射5例，瘤内注射3例。IFN-β剂量范围为2650×10⁴至10620×10⁴单位。根据小山-斋藤分类法，临床疗效为7例病情进展（PD），仅1例接受瘤内注射治疗阴道残端输卵管癌复发病灶的患者有轻微反应（MR）。IFN-β的副作用有寒战、发热、疲劳、厌食、白细胞和血小板减少以及肝功能障碍，不过这些副作用程度较轻，并非剂量限制因素。所有病例均未检测到抗IFN-β抗体。
